Exploring a new antibiotic that works without calcium against resistant bacteria
Mechanisms and In Vivo Activity of a Next Generation Daptomycin Antibiotic
This study is exploring a new type of antibiotic that could help fight tough bacterial infections, especially those that don't respond to current treatments, and it's designed for anyone who might be affected by antibiotic-resistant bacteria.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chapman University NIH-funded |
| Lab location | 1 site (Orange, United States) |
| Project ID | NIH-10734785 on NIH RePORTER |
What this research studies
This research investigates a next-generation antibiotic derived from daptomycin, which is effective against Gram-positive bacterial infections. The study focuses on developing new analogs that do not require calcium for their antibacterial activity, addressing the growing issue of bacterial resistance to existing antibiotics. Using innovative chemoenzymatic methods, the researchers aim to synthesize and evaluate these new compounds in both laboratory and animal models. The goal is to understand their mechanisms of action and effectiveness against resistant strains of bacteria.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with infections caused by Gram-positive bacteria, particularly those who have not responded to standard antibiotic treatments.
Not a fit: Patients with infections caused by Gram-negative bacteria or those who are not infected may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from antibiotic-resistant bacterial infections.
How similar studies have performed: Other research has shown promise in developing new antibiotics to combat resistant bacteria, indicating that this approach has potential for success.
Where this research is happening
Orange, United States
- Chapman University — Orange, United States (Active)
Researchers
- Principal investigator: Elshahawi, Sherif I — Chapman University
- Study coordinator: Elshahawi, Sherif I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.